KMID : 1100820200100030207
|
|
Laboratory Medicine Online 2020 Volume.10 No. 3 p.207 ~ p.213
|
|
Performance Evaluation of a Point of Care SelexOnTM B-Type Natriuretic Peptide Immunoassay
|
|
Jekarl Dong-Wook
Lee Seung-Ok Choi Hyun-Yu Cho Se-Woon Park Hae-Il
|
|
Abstract
|
|
|
Background: This study was conducted to evaluate the analytical performance of the SelexOnTM B-type natriuretic peptide (BNP) assay (Osang Healthcare Inc., Korea), a new rapid lateral flow immunoassay for point of care (POC) testing using whole blood.
Methods: The imprecision, linearity, and method comparison of SelexOnTM BNP assay were evaluated. Two commercial BNP assays, the ADVIA Centaur¢ç BNP (Siemens Health Care diagnostics Inc., USA) and the Triage¢ç BNP assays (Alere, USA), were included for method comparison using 100 whole blood samples from patients. The reference interval was verified using 120 residual samples from health examination participants.
Results: The SelexOn BNP had total CVs of 20.3%, 13.3%, and 10.3% in BNP concentrations of 89.44 pg/mL, 480.71 pg/mL, and 1,201.84 pg/mL of control materials, respectively. Linearity was observed from 56 pg/mL to 1544 pg/mL. The SelexOn BNP (y) regression equation was y=0.9706x-21.68 with Centaur BNP (x) (r=0.930) and y=0.7600x+0.0506 with Triage BNP (x) (r=0.845), respectively. The predicted mean difference (%) of the SelexOn BNP at the clinical decision levels (100 pg/mL) was up to 25% lower than the two comparative methods. The SelexOn BNP levels were below 50 pg/mL in 114 (95%) of the 120 samples.
Conclusions: The SelexOn BNP using EDTA was developed as a POC test for differential diagnosis or treatment monitoring for acute heart failure. However, clinical decision values must be improved to be compatible with other BNP methods.
|
|
KEYWORD
|
|
Point of care testing, B-type natriuretic peptide, Lateral flow immunoassay
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|